Stay updated on PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedFooter revision stamp updated from v3.6.2 to v3.6.3. This reflects a page template revision and does not alter the study details displayed.SummaryDifference0.1%

- Check9 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a new version of the ClinicalTrials.gov page rather than a substantive change to the study details.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedThe page now indicates that recruitment has ended ('No longer looking for participants'), and there are minor navigational/formatting updates (the Intervention/Treatment heading formatting, newly added help sections such as 'How to Read a Study Record', 'Common Questions', 'How to Join a Study', and an updated revision tag from v3.5.5 to v3.6.0).SummaryDifference0.4%

- Check31 days agoChange DetectedThe page revision label was updated from v3.5.4 to v3.5.5, reflecting a minor maintenance update to the site's versioning for this page. No study content or data is altered.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4, indicating a new page release in the system. The change does not alter the visible content or study data on the page.SummaryDifference0.1%

- Check74 days agoChange DetectedThe page’s footer revision/version was updated from v3.5.2 to v3.5.3, indicating a minor update to the site itself rather than a change to the clinical trial study content.SummaryDifference0.1%

Stay in the know with updates to PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.